In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
from Latest Science News -- ScienceDaily https://ift.tt/317NlC5
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment